Test Retest Reliability of Offset Analgesia and Onset Hyperalgesia Paradigm
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- University of Pittsburgh
- Enrollment
- 74
- Locations
- 2
- Primary Endpoint
- Test retest reliability of offset analgesia and onset hyperalgesia
Study Overview
Brief Summary
The goal of this study is to measure the test retest reliability of offset analgesia (OA) and onset hyperalgesia (OH) across multiple study visits. OA and OH are quantitative sensory tests (QST) thought to measure how the brain modulates pain. This study will use a heat thermode to induce OA and OH in healthy, pain-free volunteers across 3 study visits. Additional QST measures and survey data relevant to pain modulation will be collected. This study lays the foundation required to use OA and OH as tools to measure pain modulation in clinical trials. Following their validation, we anticipate that OA and OH will serve as predictive and therapeutic biomarkers, which will aid both in the development of novel analgesics and in treatment selection leading to the personalization of pain management.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Basic Science
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 50 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Healthy volunteers with no chronic pain issues who can understand the study procedures
Exclusion Criteria
- •History of chronic pain
- •Current significant pain disorder
- •Active ongoing pain every day that is acute or chronic in duration
- •Recent history of migraine (1 attack in last 24 months)
- •Lifetime history mood disorders (anxiety, depression, bipolar) or psychotic disorders.
- •Subjects taking psychotropics (e.g. benzodiazepines, antidepressants), or medications known to affect the autonomic nervous system (e.g. beta-receptor agonists or antagonists) will be excluded.
- •Cognitive impairment affecting the ability to provide informed consent, understand directions, and participate in study procedures
- •Uncontrolled or unstable medical disorder preventing participation in study procedures
- •Pregnancy
- •Tattoos on forearm
- •History of brain surgery
- •Nonambulatory status
- •Heart problems such as an irregular heart beat or coronary artery disease
- •Neurological problems such as seizure, fainting spells, recurrent severe headache, stroke, transient ischemic attack
- •High blood pressure
- •Severe liver disease
- •Severe gastrointestinal disease
- •Chronic severe infectious disease (e.g. HIV/AIDS)
Outcomes
Primary Outcomes
Test retest reliability of offset analgesia and onset hyperalgesia
Time Frame: 4 weeks post baseline
Pain intensity difference during heat stimuli measured on a 0-100 sliding scale (0 is no pain, 100 is the most intense pain imaginable) at 4 weeks after baseline
Differences in brain region activation- QST (quantitative sensory tests)
Time Frame: baseline
Difference in brain region activation (as measured by oxygenated hemoglobin, HbO) between central nervous system inhibition and control stimuli during QST procedures.
Offset analgesia and onset hyperalgesia
Time Frame: baseline
Pain intensity difference during heat stimuli measured on a 0-100 sliding scale (0 is no pain, 100 is the most intense pain imaginable) at baseline
Test retest reliability in brain region activation- QST (quantitative sensory tests)
Time Frame: 4 weeks post baseline
Difference in brain region activation (as measured by oxygenated hemoglobin, HbO) between central nervous system inhibition and control stimuli during QST procedures at 4 weeks after baseline
Secondary Outcomes
- Questionnaire score- STAI Y1 post testing(4 weeks after baseline)
- Questionnaire score- Generalized Anxiety Disorder 2-item (GAD-2)(baseline)
- Pain intensity(4 weeks after baseline)
- Differences in resting fNIRS signaling(baseline)
- Questionnaire score- State Trait Anxiety Inventory (STAI) Y1-2(baseline)
- Questionnaire score- Multidimensional Assessment of Interoceptive Awareness (MAIA) Version 2 post testing(4 weeks after baseline)
- Questionnaire score- Pain Catastrophizing Scale (PCS)(baseline)
- Questionnaire score- Situational Pain Catastrophizing Scale post testing(4 weeks after baseline)
- Questionnaire score- Beck Depression Inventory-II (BDI-II)(baseline)
- Questionnaire score- Multidimensional Assessment of Interoceptive Awareness (MAIA) Version 2(baseline)
Investigators
Benedict Alter
Assistant Professor
University of Pittsburgh